Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 PUFA add-on therapy for bipolar disorder (genotype-stratified analysis)
jRCTs041180075Completed
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of omega-3-acid ethyl esters in bipolar disorder (BD) (2 arms). Primary endpoints: MADRS improvement rate at 12 weeks (depressive phase cohort) and Relapse rate up to 52 weeks (remission cohort). Started Aug 2016; status: completed.
02
Drugs
omega-3-acid ethyl esters
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on jRCTs041180075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180075.